BACKGROUND AND PURPOSE: After the failure of first-line treatment, the clinical prognosis in @entity135 ( @entity213 ) deteriorates. Effective therapeutic strategies are limited due to the @entity137 of previous treatments and the diminished tolerance of surrounding normal tissue. This study demonstrates a promising second-line regimen, with function preserving surgical @entity5 debulking, followed by a combination of postoperative interstitial brachytherapy and a simultaneous protocol of cetuximab and @entity1311 . @entity1 AND METHODS: From January 2006 to May 2013, 197 @entity1 with @entity213 were treated with brachytherapy at the University Hospital Schleswig-Holstein Campus L  beck, including 94 @entity1 due to recurrent @entity5 . Within these, 18 @entity1 were referred to our clinic because of early @entity74 following first- or second-line treatment failure. They received the new palliative regimen. A matched-pair analysis including recurrent @entity5 stage, status of resection margins, tissue invasion and previous therapy was performed to evaluate this treatment retrospectively. @entity1349 ( @entity1349 ), disease-free survival (DFS), functional outcome and treatment @entity137 was analyzed on the basis of medical records and follow-up data. RESULTS: DFS and @entity1349 of the study group were 8.7 and 14.8  months. Whereas, DFS and @entity1349 of the control group, treated only by function preserving @entity5 debulking and brachytherapy, was 3.9 and 6.1  months respectively. This demonstrates a positive trend through the additional use of the cetuximab- @entity3907 protocol. Furthermore, no increase of therapy induced @entity137 was displayed. CONCLUSION: Pre-treated @entity1 with a further relapse benefit from the 'cetuximab- @entity3907 recurrency scheme'. It seems to be a valuable complement to @entity5 therapy, which improves @entity1349 and results in acceptable @entity137 .

Second-line treatment of recurrent @entity213 : XXXX debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab- @entity1311 protocol.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'interdisciplinary and multimodal tumor'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['taxol'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
